

# Kent Lai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534047/publications.pdf>

Version: 2024-02-01

32  
papers

1,006  
citations

430874

18  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

855  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia. <i>ACS Chemical Biology</i> , 2021, 16, 586-595.	3.4	6
2	Integrated stress response control of granulosa cell translation and proliferation during normal ovarian follicle development. <i>Molecular Human Reproduction</i> , 2021, 27, .	2.8	11
3	Pathophysiology and management of classic galactosemic primary ovarian insufficiency. <i>Reproduction and Fertility</i> , 2021, 2, R67-R84.	1.8	3
4	Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13551-13571.	6.4	2
5	Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia. <i>Molecular Therapy</i> , 2020, 28, 304-312.	8.2	38
6	Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. <i>Molecules</i> , 2020, 25, 645.	3.8	9
7	The Galactose Index measured in fibroblasts of GALT deficient patients distinguishes variant patients detected by newborn screening from patients with classical phenotypes. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 171-176.	1.1	3
8	A novel phosphoglucomutase-deficient mouse model reveals aberrant glycosylation and early embryonic lethality. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 998-1007.	3.6	13
9	Prevalence of epithelial abnormalities and high-risk human papilloma virus in cervicovaginal Pap smears of population subgroups as a guide toward evidence-based best practice. <i>Diagnostic Cytopathology</i> , 2019, 47, 648-652.	1.0	1
10	Discovery of novel inhibitors of human galactokinase by virtual screening. <i>Journal of Computer-Aided Molecular Design</i> , 2019, 33, 405-417.	2.9	14
11	Effect of genotype on galactose-1-phosphate in classic galactosemia patients. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 258-265.	1.1	7
12	Assessment of ataxia phenotype in a new mouse model of galactose-1 phosphate uridylyltransferase (GALT) deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 131-137.	3.6	8
13	Galactose-1 phosphate uridylyltransferase (GalT) gene: A novel positive regulator of the PI3K/Akt signaling pathway in mouse fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 205-212.	2.1	28
14	The Leloir Pathway of Galactose Metabolism – A Novel Therapeutic Target for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2016, 36, 6265-6272.	1.1	41
15	Structure activity relationships of human galactokinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 721-727.	2.2	20
16	GALK inhibitors for classic galactosemia. <i>Future Medicinal Chemistry</i> , 2014, 6, 1003-1015.	2.3	24
17	Subfertility and growth restriction in a new galactose-1 phosphate uridylyltransferase (GALT) - deficient mouse model. <i>European Journal of Human Genetics</i> , 2014, 22, 1172-1179.	2.8	43
18	Formal synthesis of 4-diphosphocytidyl-2-C-methyl d-erythritol from d-(+)-arabitol. <i>Tetrahedron</i> , 2012, 68, 8937-8941.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Correlation assessment among clinical phenotypes, expression analysis and molecular modeling of 14 novel variations in the human galactose-1-phosphate uridylyltransferase gene. <i>Human Mutation</i> , 2012, 33, 1107-1115.	2.5	25
20	Structure-Activity Analysis and Cell-Based Optimization of Human Galactokinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 667-672.	2.8	19
21	Galactose toxicity in animals. <i>IUBMB Life</i> , 2009, 61, 1063-1074.	3.4	106
22	High-Throughput Screening for Human Galactokinase Inhibitors. <i>Journal of Biomolecular Screening</i> , 2008, 13, 415-423.	2.6	45
23	Involvement of endoplasmic reticulum stress in a novel Classic Galactosemia model. <i>Molecular Genetics and Metabolism</i> , 2007, 92, 78-87.	1.1	68
24	Intracellular galactose-1-phosphate accumulation leads to environmental stress response in yeast model. <i>Molecular Genetics and Metabolism</i> , 2005, 86, 360-371.	1.1	57
25	Alternative pathways of galactose assimilation: could inverse metabolic engineering provide an alternative to galactosemic patients?. <i>Metabolic Engineering</i> , 2004, 6, 239-244.	7.0	17
26	Functional Analysis of the Human Galactose-1-Phosphate Uridyltransferase Promoter in Duarte and LA Variant Galactosemia. <i>Molecular Genetics and Metabolism</i> , 2001, 72, 297-305.	1.1	53
27	Structure-Function Analyses of a Common Mutation in Blacks with Transferase-Deficiency Galactosemia. <i>Molecular Genetics and Metabolism</i> , 2001, 74, 264-272.	1.1	33
28	Overexpression of Human UDP-Glucose Pyrophosphorylase Rescues Galactose-1-Phosphate Uridyltransferase-Deficient Yeast. <i>Biochemical and Biophysical Research Communications</i> , 2000, 271, 392-400.	2.1	60
29	The Biochemical Role of Glutamine 188 in Human Galactose-1-phosphate Uridyltransferase. <i>Journal of Biological Chemistry</i> , 1999, 274, 6559-6566.	3.4	44
30	Black children deficient in galactose 1-phosphate uridylyltransferase: Correlation of activity and immunoreactive protein in erythrocytes and leukocytes. <i>Journal of Pediatrics</i> , 1997, 130, 972-980.	1.8	16
31	A prevalent mutation for galactosemia among black Americans. <i>Journal of Pediatrics</i> , 1996, 128, 89-95.	1.8	112
32	Regulation of Inositol Transport in <i>Saccharomyces cerevisiae</i> Involves Inositol-induced Changes in Permease Stability and Endocytic Degradation in the Vacuole. <i>Journal of Biological Chemistry</i> , 1995, 270, 2525-2534.	3.4	77